OPI, RVNC and AQST Are Among After Hour Movers
Seeking AlphaApr 22 16:53 ET
Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties
TipRanksApr 8 03:55 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
BenzingaApr 4 16:31 ET
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
Dow JonesApr 2 14:16 ET
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform.
MT NewswiresApr 2 10:17 ET
Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects
TipRanksApr 2 00:35 ET
Express News | Oppenheimer Reiterates Perform on AN2 Therapeuticsto Perform
Moomoo 24/7Apr 1 09:13 ET
AN2 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 — Oppenheimer Reiterates Perform → Perform 02/13/2024 109.58% Leerink Partners $23 → $7 Downgr
BenzingaApr 1 09:12 ET
AN2 Therapeutics' High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
TipRanksMar 31 02:02 ET
AN2 Therapeutics GAAP EPS of -$0.57 Beats by $0.17
Seeking AlphaMar 29 06:57 ET
AN2 Therapeutics Reports FY Results
Seeking AlphaMar 28 17:11 ET
Express News | AN2 Therapeutics Q4 EPS $(0.57) Beats $(0.76) Estimate
Moomoo 24/7Mar 28 16:49 ET
AN2 Therapeutics 4Q Loss/Shr 57c >ANTX
AN2 Therapeutics 4Q Loss/Shr 57c >ANTX
Dow JonesMar 28 16:20 ET
Press Release: AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Comple
Dow JonesMar 28 16:10 ET
Catalyst Watch: Fed Rates Meeting, Nvidia CEO Speaks at GTC 2024, Reddit IPO
Seeking AlphaMar 15 15:16 ET
AN2 Therapeutics Extends Losses as Leerink Cuts on Trial Setback
Seeking AlphaFeb 13 11:26 ET
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc ra
BenzingaFeb 13 08:08 ET
AN2 Therapeutics Cut to Market Perform From Outperform by Leerink Partners
AN2 Therapeutics Cut to Market Perform From Outperform by Leerink Partners
Dow JonesFeb 13 07:50 ET
Leerink Cuts AN2 Therapeutics Stock Target to $7 From $23
InvestingFeb 13 04:02 ET
U.S. Shares Mixed at Close of Trade; Dow Jones Industrial Average up 0.33%
InvestingFeb 12 16:30 ET
No Data
No Data